Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. CN1671368 - Treatment of depression secondary to pain (DSP)

Office
Chine
Numéro de la demande 03817458.8
Date de la demande 24.07.2003
Numéro de publication 1671368
Date de publication 21.09.2005
Type de publication A
CIB
A61K 31/165
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
31Préparations médicinales contenant des ingrédients actifs organiques 
16Amides, p.ex. acides hydroxamiques
165ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide
CPC
A61K 31/131
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
131acyclic
A61K 31/135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
A61K 31/165
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
A61P 25/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
02for peripheral neuropathies
A61P 25/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
24Antidepressants
Déposants Cypress Bioscience Inc.
柏树生物科学公司
Inventeurs Rao Srinivas G.
斯利尼瓦斯·G·拉奥
Kranzler Jay D.
杰·D·克兰兹勒
Mandataires sun haochen
北京科龙寰宇知识产权代理有限责任公司
Données relatives à la priorité 60/398,676 24.07.2002 US
60/443,035 28.01.2003 US
Titre
(EN) Treatment of depression secondary to pain (DSP)
(ZH) 疼痛继发性抑郁(DSP)的治疗
Abrégé
(EN) Methods for the prevention or treatment of a typical depression secondary to pain (DSP) have been developed. The method generally involves administering an effective amount of a monoamine re uptake inhibitor to treat or prevent symptoms of DSP. In a preferred embodiment, a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor (SRNI) compound of a specific type, or a pharmaceutically acceptable salt thereof is administered. The most preferred SNRI compounds are non-tricyclic SNRIs, wherein serotonin reuptake inhibition is greater than norepinephrine reuptake inhibition; and NSRIs, wherein norepinephrine reuptake inhibition is greater than serotonin reuptake inhibition. The most preferred compound is milnacipran or a bioequivalent or pharmaceutically acceptable salt thereof. Other preferred compounds are duloxetine and venlafaxine or a bioequivalent or pharmaceutically acceptable salt thereof. In yet another embodiment, a therapeutically effective amount of a non-tricyclic triple reuptake inhibitor ('TRI') compound of a specific type, or a pharmaceutically acceptable salt thereof, is administered. The TRI compounds are characterized by their ability to block the reuptake (and, hence, increase central concentrations of) the three primary brain monoamines: serotonin, noradrenaline, and dopamine.
(ZH)

本发明研发出了治疗或预防非典型疼痛继发性抑郁(DSP)的方法。本方法通常包括给药有效剂量的单胺再摄取抑制剂以治疗或预防DSP症状。在优选实施方案中,给药一特定类型治疗有效剂量的双重血清素去甲肾上腺素再摄取抑制剂(SRNI)化合物或其药物可接受盐。最优选SNRI化合物是非三环的SNRIs化合物,其中对血清素再摄取抑制作用强于对去甲肾上腺素再摄取抑制作用;NSRIs,其中对去甲肾上腺素再摄取抑制作用强于对血清素再摄取抑制作用。最优选的化合物是米那普仑或其生物等效或药物可接受盐。其它优选的化合物是度洛西汀(duloxetine),文拉法新(venlafaxine)或其生物等效或药物可接受盐。在另一实施方案中,给药了一特定类型治疗有效剂量非三环三重再摄取抑制剂(“TRI”)化合物,或其药物可接受盐。TRI化合物特征在于能阻断三种主要的大脑单胺:血清素,去甲肾上腺素和多巴胺的再摄取(并因此增加中枢浓度)。